Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Hereditary Angioedema Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The hereditary angioedema market experienced robust expansion recently, projected to ascend from $2.81 billion in 2025 to $3.04 billion in 2026, reflecting an 8.2% compound annual growth rate. This historical growth trajectory is underpinned by heightened awareness of infrequent genetic conditions, the accessibility of plasma-derived C1 esterase inhibitors, the proliferation of specialized treatment facilities, enhanced diagnostic precision for HAE, and the vigorous efforts of patient advocacy groups.

The market for hereditary angioedema is projected for significant expansion in the upcoming years, anticipating a rise to $4.15 billion by 2030 with a cumulative annual growth rate of 8.0%. This forecasted expansion is underpinned by advancements in novel oral and subcutaneous treatment options, increased financial backing for the development of rare disease medications, a greater embrace of individualized medical treatments, the proliferation of genetic screening initiatives, and more effective long-term strategies for managing the condition. Key developments anticipated during this period involve a greater utilization of targeted bradykinin therapies, a rise in the application of preventative treatment plans, a heightened emphasis on identifying the condition through genetic testing at an earlier stage, the wider availability of therapies that patients can administer themselves at home, and the implementation of patient-focused treatment methodologies.

The hereditary angioedema market is poised for robust expansion, anticipated to reach $4.15 billion by 2030, driven by a compound annual growth rate of 8.0%. This growth trajectory is fueled by the introduction of new oral and subcutaneous therapies, increased investment in the development of drugs for rare diseases, a growing trend towards personalized medicine, expanding genetic screening programs, and refined long-term disease management techniques. During the forecast period, significant trends include the increasing adoption of targeted bradykinin therapies, a greater prevalence of prophylactic treatment regimens, a concentrated effort on early genetic diagnosis, the expansion of home-based self-administration of therapies, and the development of more patient-centered treatment approaches.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

Hereditary Angioedema Market Demand Drivers Creating New Revenue Opportunities

The increasing incidence of rare diseases is anticipated to be a key driver for the expansion of the hereditary angioedema market. Rare diseases, often termed orphan diseases, are characterized by their low prevalence within the general population. This rise in rare conditions can be attributed to several contributing factors, including advancements in medical science, shifts in demographic patterns, and environmental influences. Hereditary angioedema (HAE), a notable example of a rare disease, underscores the critical need for specialized interventions and heightened awareness due to its potentially fatal swelling attacks. The inherent rarity and genetic basis of HAE necessitate prompt diagnosis and tailored treatment strategies to ensure effective patient management and better prognoses. For elucidation, consider the projection from The American Cancer Society in January 2025, which estimates that by 2025, approximately 59,660 new diagnoses of oral cavity and oropharyngeal cancer will occur in the U.S., with an estimated 12,770 fatalities from these specific cancers. Consequently, the escalating occurrence of rare diseases directly fuels the growth trajectory of the hereditary angioedema market.

Hereditary Angioedema Market Segmentation Trends And Revenue Drivers

The hereditary angioedema market covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis, On-demand

3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes

4) By Route Of Administration: Subcutaneous, Intravenous, Oral

5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

Hereditary Angioedema Market Trends Driving Strategic Industry Expansion

The hereditary angioedema market is witnessing significant advancements driven by key players introducing novel therapeutic approaches, notably oral plasma kallikrein inhibitors, aimed at delivering enhanced convenience and efficacy for patients requiring on-demand treatment. These inhibitors function by impeding plasma kallikrein, thereby curbing excessive bradykinin generation, and are specifically utilized in the management of hereditary angioedema. A notable development occurred in September 2024 when KalVista Pharmaceuticals, Inc., an American pharmaceutical firm, revealed that its new drug application for sebetralstat had been accepted by the FDA. This experimental oral plasma kallikrein inhibitor is being developed as a treatment option for acute hereditary angioedema attacks in individuals aged 12 and above, encompassing both adults and younger patients, and offers a fresh therapeutic strategy by directly targeting plasma kallikrein activity. The acceptance of this application marks a crucial step towards the potential regulatory approval and subsequent market introduction of sebetralstat.

Hereditary Angioedema Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

Access The Complete Hereditary Angioedema Market Report:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Hereditary Angioedema Market Regional Analysis: Which Region Leads By Revenue?

North Americawas the largest region in the hereditary angioedema market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model